Contents
pdf Download PDF
pdf Download XML
82 Views
12 Downloads
Share this article
Research Article | Volume 18 Issue 11 (November, 2026) | Pages 348 - 359
Impact of a Structured Antimicrobial Stewardship and Infection Prevention Intervention on Hospital-Acquired Infection Rates and Resistance Patterns: A Pre-Post Quasi-Experimental Study
 ,
 ,
 ,
1
Assistant Professor, Department of Microbiology, Integral Institute of Medical Sciences and Research, Lucknow, Uttar Pradesh, India,
2
Associate Professor Department of Microbiology Chettinad Hospital and Research Institute, Chettinad Academy of Research and Education, Kelambakkam, Chengalpattu, India,
3
Professor, Department of Microbiology, NAMO Medical Education and Research Institute, Silvassa, India,
4
Assistant Professor, Department of Microbiology, NAMO Medical Education and Research Institute, Silvassa, India.
Under a Creative Commons license
Open Access
Received
Sept. 18, 2026
Revised
Oct. 10, 2026
Accepted
Oct. 25, 2026
Published
Nov. 17, 2026
Abstract

Introduction: Healthcare-associated infections (HAIs) caused by carbapenem-resistant gram-negative bacteria are common in Indian tertiary hospitals. Few Indian studies have tested combined antimicrobial stewardship (AMS) and infection prevention and control (IPC) programmes against infection, consumption and resistance outcomes together. Objective: To assess whether a structured, microbiologist-led AMS and IPC intervention reduces HAI incidence, antimicrobial consumption and antimicrobial resistance. Design, setting, and participants: Pre-post quasi-experimental study with interrupted time-series (ITS) analysis in 3 adult intensive care units (ICUs) and 14 adult wards of a 650-bed tertiary care teaching hospital in India. All adults admitted for 48 hours or longer during the preintervention period (January–December 2024; 18,950 admissions; 130,272 patient-days) and the postintervention period (April 2025–March 2026; 19,438 admissions; 130,852 patient-days) were included. January–March 2025 was the implementation phase and was excluded. Intervention: A bundled programme with 4 components: prospective audit and feedback with a 48–72-hour antibiotic time-out; restriction of carbapenems, polymyxins and other Reserve-group agents; an antibiogram-based treatment and surgical prophylaxis policy; and a multimodal IPC package covering hand hygiene, device bundles and contact precautions. Main outcomes and measures: The primary outcome was overall HAI incidence per 1000 patient-days. Secondary outcomes were device-associated infection rates, surgical site infection (SSI), antimicrobial days of therapy (DOT) per 1000 patient-days, resistance proportions and multidrug-resistant organism (MDRO) incidence, and in-hospital mortality. Results: Hand hygiene compliance rose from 45.8% to 78.4%. Overall, HAI incidence fell from 5.97 to 3.48 per 1000 patient-days (incidence rate ratio [IRR], 0.58; 95% CI, 0.52–0.66; P < .001). The ITS level change was IRR 0.63 (95% CI, 0.48–0.82), and the case-mix–adjusted IRR was 0.64 (95% CI, 0.49–0.84). Central line–associated bloodstream infection fell by 48% (IRR, 0.52; 95% CI, 0.36–0.74), catheter-associated urinary tract infection by 41% and ventilator-associated pneumonia by 37%. SSI fell from 4.6% to 2.7% (risk ratio [RR], 0.59; 95% CI, 0.49–0.71). Total DOT fell by 17.2% and carbapenem DOT by 35.6%. Carbapenem resistance declined in Klebsiella pneumoniae (67.0% to 59.7%; RR, 0.89; 95% CI, 0.80–0.99), Acinetobacter baumannii (88.7% to 80.7%) and Pseudomonas aeruginosa (42.2% to 29.3%). Incidence of hospital-onset carbapenem-resistant Enterobacterales fell by 31% (IRR, 0.69; 95% CI, 0.55–0.88). Resistance in community-onset outpatient Escherichia coli, a nonequivalent control outcome, was unchanged (58.7% vs 58.8%). Mortality did not differ (6.7% vs 6.4%; RR, 0.96; 95% CI, 0.89–1.03). Conclusions and relevance: A combined AMS and IPC intervention was associated with fewer HAIs, lower carbapenem use and lower carbapenem resistance within 12 months, with no rise in mortality. Multicenter controlled ITS studies should test whether these effects hold and persist.

Keywords
INTRODUCTION

Bacterial antimicrobial resistance (AMR) was directly responsible for an estimated 1.27 million deaths and associated with 4.95 million deaths worldwide in 2019.¹ WHO surveillance data for 2023 show that about 1 in 6 laboratory-confirmed bacterial infections worldwide were resistant to antibiotics. In the WHO South-East Asia Region, the figure was about 1 in 3.²

 

Healthcare-associated infections (HAIs) are a main route by which resistant organisms reach patients. In low- and middle-income countries the pooled HAI prevalence is about twice that of high-income settings. ³ Indian surveillance confirms a high burden. In the International Nosocomial Infection Control Consortium (INICC) network, adult and paediatrics ICUs reported 5.1 central line–associated bloodstream infections (CLABSIs) and 9.4 ventilator-associated pneumonias (VAPs) per 1000 device-days.⁴ In the national HAI surveillance network of 26 tertiary hospitals, 72% of Klebsiella bloodstream infections and 77% of Acinetobacter bloodstream infections were carbapenem resistant.⁵ The ICMR AMR Research and Surveillance Network continues to report rising carbapenem resistance in K pneumoniae and A baumannii, with the highest levels in ICUs.⁶ High antibiotic consumption, unregulated access and weak infection control drive these trends.⁷

 

Two strategies address this problem from different directions. Antimicrobial stewardship (AMS) reduces selection pressure by improving antibiotic choice, dose and duration.⁸˒⁹ Infection prevention and control (IPC) reduces transmission and the number of infections that need treatment at all.¹⁰ A Cochrane review of 221 studies found that hospital stewardship interventions increased guideline-compliant prescribing and shortened treatment without increasing mortality.¹¹ A meta-analysis of 32 studies found that stewardship reduced colonization and infection with multidrug-resistant gram-negative bacteria by 51%. The effect was largest when stewardship was combined with IPC measures, particularly hand hygiene.¹² Landmark single-component IPC programmes have also cut HAIs substantially.¹³˒¹⁴

 

The evidence from India is thinner. A meta-analysis of Asian stewardship programmes found consistent reductions in antibiotic use but no pooled effect on HAI, except in programmes that included infection control or hand hygiene.¹⁵ Indian studies have mostly reported process and cost outcomes from single stewardship programmes.¹⁶ National policy documents, ICMR stewardship guidelines and the National Action Plan on AMR 2.0 (2025–2029) all call for hospital-level AMS and IPC programmes.¹⁷⁻¹⁹ Few evaluations, however, have measured HAI incidence, antimicrobial consumption and resistance together. Fewer still have used designs that separate an intervention effect from secular trends. ²⁰

 

We therefore evaluated a structured, microbiologist-led AMS and IPC intervention in a tertiary teaching hospital. We used a pre-post design with interrupted time-series analysis and a nonequivalent dependent variable.

 

Objectives. The primary objective was to measure the change in overall HAI incidence per 1000 patient-days. The secondary objectives were to measure changes in device-associated infections, surgical site infection (SSI), antimicrobial consumption, resistance proportions in key pathogens, MDRO incidence and in-hospital mortality.

 

Hypothesis. We hypothesised that the intervention would reduce overall HAI incidence by at least 25%, with no increase in mortality.

MATERIALS AND METHODS

Study design and reporting

This was a single-centre, pre-post quasi-experimental study with interrupted time-series (ITS) analysis of monthly data. It included a nonequivalent dependent variable to detect secular confounding.²⁰ The report follows the TREND statement, the ORION statement for intervention studies of nosocomial infection, and SQUIRE 2.0.²¹⁻²³

 

Setting

The study took place in a 650-bed public tertiary care teaching hospital in India. The hospital has about 26,000 adult admissions a year and an NABL-accredited microbiology laboratory. The study units were 3 adult ICUs with 60 beds (medical 24, surgical 20, emergency and trauma 16) and 14 adult medical and surgical wards with 360 beds. Paediatric, neonatal and obstetric units were excluded because they have a different case mix and a separate neonatal IPC programme.

Before the intervention, the hospital had a Hospital Infection Control Committee and 2 infection control nurses. Prospective HAI surveillance had run since July 2023, using the same definitions and the same team as during the study. There was no stewardship team, no restricted-antimicrobial policy and no antibiogram-based treatment guideline.

 

Study periods

  • Preintervention (usual care): January 1 to December 31, 2024 (12 months).
  • Implementation (washout): January 1 to March 31, 2025. Training, policy roll-out and staged introduction of each component. Excluded from the primary analysis (Figure 1).
  • Postintervention: April 1, 2025, to March 31, 2026 (12 months).

 

Participants

All patients aged 18 years or older admitted to a study unit for 48 hours or longer were eligible. Day-care admissions and stays shorter than 48 hours were excluded. Infections present on admission (onset before hospital day 3) were not counted as HAIs. Each patient contributed patient-days for every day spent in a study unit. Device-days were counted daily at 08:00 by ICU nurses.

 

Intervention

A multidisciplinary AMS team ran the programme. It was led by a clinical microbiologist and included an intensivist, an internal medicine physician, a clinical pharmacologist, a pharmacist and the senior infection control nurse. The design followed the ICMR Antimicrobial Stewardship Program Guideline and the WHO core components for IPC programmes.¹⁰˒¹⁸ Table 1 lists the components.

 

Outcome definitions

HAIs were identified by prospective surveillance by trained infection control nurses. The microbiologist validated each case. Definitions followed the CDC National Healthcare Safety Network (NHSN) Patient Safety Component Manual, January 2024, as adapted for the Indian HAI surveillance network. ⁵˒³⁰

  • Primary outcome: overall HAI incidence per 1000 patient-days. This counted CLABSI, catheter-associated urinary tract infection (CAUTI), VAP, SSI and other HAIs. Other HAIs were bloodstream infections not linked to a central line, hospital-acquired pneumonia in non-ventilated patients, Clostridioides difficile infection and other site-specific infections.
  • Device-associated infections: CLABSI per 1000 central line–days, CAUTI per 1000 urinary catheter–days and VAP per 1000 ventilator-days in ICUs.
  • SSI: SSIs per 100 clean and clean-contaminated procedures, with 30-day or 90-day follow-up (90 days for implants), using NHSN criteria.
  • Antimicrobial use: days of therapy (DOT) per 1000 patient-days, from the electronic dispensing and administration record. Each systemic antibacterial given on a calendar day counted as 1 DOT.³¹ Totals were also reported by class and by AWaRe group.
  • Resistance: the proportion of resistant isolates among the first hospital-onset clinical isolate per patient per period. A hospital-onset isolate came from a specimen collected on or after hospital day 3. Screening isolates were excluded. Resistance markers were carbapenem resistance in K pneumoniae, E coli, A baumannii and P aeruginosa; third-generation cephalosporin (3GC) resistance in K pneumoniae and E coli; methicillin resistance in S aureus (MRSA); and vancomycin resistance in Enterococcus spp (VRE).
  • MDRO incidence: new hospital-onset clinical isolates of carbapenem-resistant Enterobacterales (CRE), carbapenem-resistant A baumannii (CRAB) and MRSA per 1000 patient-days. MDR and XDR were defined by international consensus criteria. ³²
  • Process measures: hand hygiene compliance, bundle compliance, cultures taken before the first antibiotic dose, surgical prophylaxis beyond 24 hours, documented time-outs, empirical therapy that matched the policy, and acceptance of PAF recommendations.
  • Balancing measures: all-cause in-hospital mortality and length of stay.
  • Nonequivalent dependent variable: 3GC resistance in community-onset E coli from outpatient urine cultures. The intervention should not affect this outcome, so a change would point to a secular trend or a laboratory artefact.²⁰

 

Microbiology

Isolates were identified by MALDI-TOF mass spectrometry or VITEK 2 (bioMérieux). Antimicrobial susceptibility testing used VITEK 2 AST cards with disc diffusion confirmation, interpreted against the CLSI M100 34th edition breakpoints for the whole study.³³ Colistin susceptibility was tested by broth microdilution. Quality control used ATCC reference strains, and the laboratory took part in external quality assessment throughout. Breakpoints and testing platforms did not change during the study.

 

Sample size

We assumed a baseline HAI incidence of 6.0 per 1000 patient-days and set out to detect a 25% reduction (to 4.5 per 1000 patient-days) with 80% power and two-sided α = .05. This needed about 36,600 patient-days per period. Each period was expected to provide about 130,000 patient-days. For ITS analysis we used 12 monthly data points before and after the intervention, the minimum recommended for segmented regression.³⁴

 

Statistical analysis

Baseline characteristics were compared using standardised mean differences (SMDs). An SMD above 0.10 was taken to indicate meaningful imbalance. Rates were compared as incidence rate ratios (IRRs) with Wald 95% CIs on the log scale and exact conditional binomial P values. Proportions were compared as risk ratios (RRs) using the χ² test, or Fisher exact test when any expected cell count was below 5.

The primary ITS analysis used segmented quasi-Poisson regression of monthly HAI counts, with the logarithm of patient-days as an offset.³⁵˒³⁶

The adjusted model added monthly mean Charlson Comorbidity Index and ICU share of patient-days. Device utilisation was not adjusted for, because reducing device use was part of the intervention and so lies on the causal pathway. Antimicrobial consumption was modelled with segmented linear regression and Newey-West standard errors (lag 3).

We ran 2 sensitivity analyses: negative binomial regression in place of quasi-Poisson, and inclusion of the implementation months in the postintervention period. Monthly denominators were complete. Isolates without susceptibility results were excluded (less than 1% of isolates). Secondary outcomes were not adjusted for multiple comparisons and are interpreted as exploratory.

All tests were two-sided with α = .05. Analyses were run in Python 3.13 with statsmodels 0.15 and SciPy

RESULTS

Table 1. Components of the antimicrobial stewardship and infection prevention intervention

Component

Content

Frequency

Lead

Governance

AMS committee reporting to the Medical Superintendent; joint AMS–HICC review of unit dashboards

Monthly

Microbiologist (chair)

Treatment and prophylaxis policy

Empirical treatment guideline built from the 2024 cumulative antibiogram; single-dose surgical prophylaxis given within 60 min of incision and stopped by 24 h

Policy issued Jan 2025; antibiogram updated yearly

AMS team

Restriction

Carbapenems, polymyxins, tigecycline, ceftazidime-avibactam and linezolid released for 24 h on a justification form; continuation needs AMS approval

Daily

Microbiologist, pharmacist

Prospective audit and feedback (PAF)

Review of all restricted agents and of every ICU antibiotic course past 72 h; written recommendation in the case record and a phone call to the treating team

Weekdays

AMS team

Antibiotic time-out

Printed 48–72 h checklist in the drug chart: diagnosis confirmed, cultures reviewed, de-escalate, switch to oral, stop date set

Every course

Treating physician

Diagnostic stewardship

Paired blood cultures before the first dose; no urine culture from catheterised patients without symptoms; same-day phoned reports of positive blood cultures and MDRO flags

Continuous

Microbiology laboratory

Hand hygiene

WHO multimodal strategy: alcohol-based handrub at every bedside, training, direct observation of the 5 moments, unit feedback and reminders²⁴

Observation audits monthly

IPC nurses

Device and SSI bundles

CLABSI, CAUTI, VAP and SSI bundles adapted from current SHEA/IDSA/APIC compendium recommendations, with daily ICU checklists and a daily review of whether each device is still needed²⁵⁻²⁸

Daily checklists; monthly audits

ICU nurse champions

MDRO control

Contact precautions and cohorting for CRE and CRAB; rectal screening for CRE at ICU admission; daily chlorhexidine bathing in ICUs; terminal cleaning audited with fluorescent markers

Continuous

IPC team

Education and feedback

Induction and quarterly sessions for residents and nurses; monthly unit-level HAI and antibiotic-use reports

Monthly

AMS and IPC teams

Antibiotics were grouped into Access, Watch and Reserve categories using the WHO AWaRe classification.²⁹

 

Study population

The preintervention period had 18,950 admissions and 130,272 patient-days. The postintervention period had 19,438 admissions and 130,852 patient-days. The two populations were well balanced: no baseline characteristic had an SMD above 0.10 (Table 2). With these large samples, small differences in age, Charlson index and ICU admission reached statistical significance. Mean length of stay was 6.9 days before and 6.7 days after the intervention.

 

Table 2. Baseline characteristics and exposure denominators

Characteristic

Preintervention (n = 18,950)

Postintervention (n = 19,438)

SMD

Age, mean ± SD, y

52.7 ± 16.7

53.5 ± 16.8

0.044

Male, No. (%)

11,070 (58.4)

11,387 (58.6)

0.003

Charlson Comorbidity Index, median (IQR)

3 (2–4)

3 (2–4)

0.055

ICU admission, No. (%)

3,021 (15.9)

3,260 (16.8)

0.022

Surgical admission, No. (%)

6,488 (34.2)

6,778 (34.9)

0.013

Diabetes mellitus, No. (%)

4,430 (23.4)

4,595 (23.6)

0.006

Chronic kidney disease, No. (%)

1,582 (8.3)

1,734 (8.9)

0.020

Active malignancy, No. (%)

1,286 (6.8)

1,348 (6.9)

0.006

Transferred from another facility, No. (%)

3,579 (18.9)

3,727 (19.2)

0.007

Patient-days

130,272

130,852

—

ICU patient-days (% of total)

19,157 (14.7)

19,078 (14.6)

—

Clean and clean-contaminated procedures

6,464

6,566

—

Central line utilisation ratio

0.43

0.40

—

Urinary catheter utilisation ratio

0.63

0.56

—

Ventilator utilisation ratio

0.32

0.30

—

Abbreviation: SMD, standardised mean difference. Utilisation ratios are device-days divided by ICU patient-days.

 

Process measures

All process measures improved (Table 3). Hand hygiene compliance rose from 45.8% to 78.4%, an absolute gain of 32.5 percentage points. Compliance with the 3 device bundles roughly doubled to 83%–87%. Surgical prophylaxis continued beyond 24 hours fell from 65.0% to 22.5%. The AMS team made 1735 PAF recommendations, and prescribers accepted 1305 (75.2%; 95% CI, 73.1%–77.2%).

 

Table 3. Process measures before and after the intervention

Measure

Preintervention, No./total (%)

Postintervention, No./total (%)

RR (95% CI)

P value

Hand hygiene compliance (observed opportunities)

2241/4890 (45.8)

4175/5328 (78.4)

1.71 (1.65–1.77)

< .001

CLABSI insertion and maintenance bundle

122/312 (39.1)

287/344 (83.4)

2.13 (1.84–2.47)

< .001

VAP prevention bundle

135/296 (45.6)

276/330 (83.6)

1.83 (1.61–2.10)

< .001

CAUTI prevention bundle

121/288 (42.0)

277/318 (87.1)

2.07 (1.80–2.39)

< .001

Blood culture before first antibiotic dose

432/820 (52.7)

688/864 (79.6)

1.51 (1.40–1.63)

< .001

Empirical therapy matching the hospital policy

257/560 (45.9)

466/602 (77.4)

1.69 (1.53–1.86)

< .001

48–72 h time-out documented

50/600 (8.3)

462/640 (72.2)

8.66 (6.61–11.34)

< .001

Surgical prophylaxis beyond 24 h

416/640 (65.0)

150/668 (22.5)

0.35 (0.30–0.40)

< .001

Primary outcome: overall HAI incidence

The study recorded 778 HAIs before and 456 after the intervention. Overall incidence fell from 5.97 to 3.48 per 1000 patient-days, a 41.6% reduction (IRR, 0.58; 95% CI, 0.52–0.66; P < .001) (Table 4).

The preintervention trend was flat (monthly IRR, 1.008; 95% CI, 0.986–1.030; P = .48). The intervention was followed by an immediate level drop (IRR, 0.63; 95% CI, 0.48–0.82; P < .001). The postintervention slope also declined, but not significantly (monthly IRR, 0.971; 95% CI, 0.937–1.006; P = .11) (Table 7; Figure 2). Taking level and slope together, incidence at month 12 was an estimated 56% below the projected counterfactual. After adjustment for case mix, the level change was unchanged (IRR, 0.64; 95% CI, 0.49–0.84; P = .001).

Figure 2 · approximate working data, 27 months (Jan 2024–Mar 2026); fit from the quasi-Poisson segmented model, plotted for non-monsoon months

 

By month 12 after the intervention, the fitted rate (2.93) was 56% below the projected preintervention trend (6.65).

 

Secondary outcomes: device-associated infection and SSI

Every HAI type declined (Table 4). CLABSI fell by 48.3% (IRR, 0.52; 95% CI, 0.36–0.74), CAUTI by 41.0% (IRR, 0.59; 95% CI, 0.40–0.88) and VAP by 36.8% (IRR, 0.63; 95% CI, 0.47–0.84). SSI fell from 4.6% to 2.7% of procedures (RR, 0.59; 95% CI, 0.49–0.71). In ITS analysis, device-associated HAI per 1000 ICU patient-days showed a level drop of 49% (IRR, 0.51; 95% CI, 0.33–0.77; P = .002). Device utilisation also fell, most for urinary catheters (0.63 to 0.56).

 

Table 4. Healthcare-associated infection outcomes

Outcome

Preintervention, events/exposure

Preintervention rate

Postintervention, events/exposure

Postintervention rate

IRR or RR (95% CI)

P value

Overall HAI, per 1000 patient-days

778/130,272

5.97

456/130,852

3.48

0.58 (0.52–0.66)

< .001

Device-associated HAI, per 1000 device-days

288/26,294

10.95

155/23,953

6.47

0.59 (0.49–0.72)

< .001

CLABSI, per 1000 central line–days

93/8179

11.37

45/7652

5.88

0.52 (0.36–0.74)

< .001

CAUTI, per 1000 urinary catheter–days

71/12,049

5.89

37/10,648

3.47

0.59 (0.40–0.88)

.009

VAP, per 1000 ventilator-days

124/6066

20.44

73/5653

12.91

0.63 (0.47–0.84)

.002

Other HAIs, per 1000 patient-days

190/130,272

1.46

121/130,852

0.92

0.63 (0.50–0.80)

< .001

SSI, per 100 procedures

300/6464

4.6

180/6566

2.7

0.59 (0.49–0.71)ᵃ

< .001

Abbreviations: CAUTI, catheter-associated urinary tract infection; CLABSI, central line–associated bloodstream infection; IRR, incidence rate ratio; RR, risk ratio; SSI, surgical site infection; VAP, ventilator-associated pneumonia. ᵃ Risk ratio. All other ratios are IRRs with exact conditional P values.

 

Antimicrobial consumption

Mean monthly antimicrobial use fell from 920.2 to 761.6 DOT per 1000 patient-days, a 17.2% reduction (Table 5). Carbapenem use fell by 35.6%, polymyxin use by 31.3% and Reserve-group use by 36.3%. The share of Access antibiotics rose from 28.5% to 38.7% of all DOT.

In ITS analysis, carbapenem use dropped by 39.1 DOT per 1000 patient-days at the start of the postintervention period (95% CI, −42.7 to −35.6). It then fell by a further 2.2 DOT per month (95% CI, −2.7 to −1.7), reversing a rising preintervention trend (Table 7; Figure 3).

 

Table 5. Antimicrobial consumption, DOT per 1000 patient-days

Antimicrobial group

Preintervention, mean ± SD

Postintervention, mean ± SD

Absolute change

Relative change, %

P value

All systemic antibacterials

920.2 ± 28.4

761.6 ± 22.8

−158.6

−17.2

< .001

Third-generation cephalosporins

190.5 ± 6.2

156.3 ± 6.2

−34.2

−18.0

< .001

Carbapenems

121.6 ± 4.1

78.3 ± 5.9

−43.3

−35.6

< .001

Polymyxins

32.3 ± 1.3

22.2 ± 1.1

−10.1

−31.3

< .001

WHO AWaRe Reserve group

55.2 ± 2.4

35.1 ± 1.6

−20.1

−36.3

< .001

WHO AWaRe Access group

261.7 ± 8.6

295.0 ± 9.1

+33.2

+12.7

< .001

Access share of total DOT, %

28.5

38.7

+10.3 points

RR 1.36 (1.35–1.38)

< .001

Abbreviation: DOT, days of therapy. Means are of 12 monthly rates per period, compared by t test.

Figure 3 · approximate working data, 27 months (Jan 2024–Mar 2026); fit from segmented linear regression with Newey-West errors, plotted for non-monsoon months

The projected line extends a rising preintervention trend, so it overstates the counterfactual if that rise would have levelled off. The observed fall from 121.6 to 78.3 DOT per 1000 patient-days does not depend on this projection.

 

Resistance and MDRO incidence

Carbapenem resistance fell in all 3 priority gram-negative pathogens (Table 6). It fell in K pneumoniae from 67.0% to 59.7% (RR, 0.89; 95% CI, 0.80–0.99; P = .03), in A baumannii from 88.7% to 80.7% (RR, 0.91; 95% CI, 0.85–0.98; P = .01) and in P aeruginosa from 42.2% to 29.3% (RR, 0.69; 95% CI, 0.53–0.91; P = .008). 3GC resistance in E coli fell from 81.0% to 72.7% (P = .009).

The declines in carbapenem-resistant E coli, MRSA and VRE were not statistically significant. Hospital-onset incidence fell by 31% for CRE, 32% for CRAB and 43% for MRSA.

The nonequivalent dependent variable did not change. 3GC resistance in community-onset outpatient E coli was 58.7% before and 58.8% after the intervention (RR, 1.00; 95% CI, 0.94–1.07; P = .98).

 

Table 6. Resistance proportions and MDRO incidence in hospital-onset clinical isolates

Organism and resistance marker

Preintervention, resistant/tested (%)

Postintervention, resistant/tested (%)

RR or IRR (95% CI)

P value

K pneumoniae, carbapenem

280/418 (67.0)

222/372 (59.7)

0.89 (0.80–0.99)

.03

K pneumoniae, 3GC

355/418 (84.9)

304/372 (81.7)

0.96 (0.90–1.02)

.23

E coli, carbapenem

68/352 (19.3)

51/344 (14.8)

0.77 (0.55–1.07)

.12

E coli, 3GC

285/352 (81.0)

250/344 (72.7)

0.90 (0.83–0.97)

.009

A baumannii, carbapenem

258/291 (88.7)

197/244 (80.7)

0.91 (0.85–0.98)

.01

P aeruginosa, carbapenem

86/204 (42.2)

55/188 (29.3)

0.69 (0.53–0.91)

.008

S aureus, methicillin (MRSA)

87/168 (51.8)

67/152 (44.1)

0.85 (0.68–1.07)

.17

Enterococcus spp, vancomycin (VRE)

12/121 (9.9)

12/126 (9.5)

0.96 (0.45–2.05)

.92

CRE incidence, per 1000 patient-days

162 (1.24)

113 (0.86)

0.69 (0.55–0.88)ᵃ

.003

CRAB incidence, per 1000 patient-days

134 (1.03)

92 (0.70)

0.68 (0.52–0.89)ᵃ

.005

MRSA incidence, per 1000 patient-days

66 (0.51)

38 (0.29)

0.57 (0.38–0.85)ᵃ

.006

Control outcome: community-onset OPD urine E coli, 3GC

728/1240 (58.7)

745/1268 (58.8)

1.00 (0.94–1.07)

.98

Abbreviations: 3GC, third-generation cephalosporin; CRAB, carbapenem-resistant A baumannii; CRE, carbapenem-resistant Enterobacterales; MRSA, methicillin-resistant S aureus; OPD, outpatient department; VRE, vancomycin-resistant enterococci. ᵃ IRR. Incidence rows show No. of new isolates (rate).

 

Interrupted time-series estimates

Table 7 gives all segmented-regression estimates. The models showed no material overdispersion (Pearson χ²/df, 0.86–1.02) and no significant residual autocorrelation at lag 6.

 

Table 7. Segmented regression estimates

Outcome (model)

Preintervention trend, per month (95% CI)

Level change (95% CI)

Slope change, per month (95% CI)

Durbin-Watson

Overall HAI per 1000 patient-days (quasi-Poisson), IRR

1.008 (0.986–1.030)

0.63 (0.48–0.82); P < .001

0.971 (0.937–1.006); P = .11

2.76

Overall HAI, adjusted for case mixᵃ, IRR

1.003 (0.983–1.024)

0.64 (0.49–0.84); P = .001

0.974 (0.940–1.009); P = .15

2.87

Device-associated HAI per 1000 ICU patient-days, IRR

1.013 (0.980–1.046)

0.51 (0.33–0.77); P = .002

0.982 (0.928–1.038); P = .51

2.68

Total DOT per 1000 patient-days (linear, Newey-West), β

+6.1 (3.7 to 8.4)

−181.0 (−205.8 to −156.2); P < .001

−10.5 (−13.7 to −7.4); P < .001

1.86

Carbapenem DOT per 1000 patient-days (linear, Newey-West), β

+0.7 (0.3 to 1.1)

−39.1 (−42.7 to −35.6); P < .001

−2.2 (−2.7 to −1.7); P < .001

1.59

All models include a monsoon-season term (July–September). ᵃ Adjusted for monthly mean Charlson Comorbidity Index and ICU share of patient-days.

 

Sensitivity analyses and balancing measures

The results held in both sensitivity analyses. Negative binomial regression gave the same level change (IRR, 0.63; 95% CI, 0.48–0.82). The estimated dispersion was close to 0, which supports the Poisson model. Counting the implementation months as postintervention made the effect smaller but it stayed significant (IRR, 0.77; 95% CI, 0.63–0.95; P = .01). This fits a phased roll-out during January to March 2025.

In-hospital mortality was 6.7% (1273/18,950) before and 6.4% (1250/19,438) after the intervention (RR, 0.96; 95% CI, 0.89–1.03; P = .26). Median length of stay was unchanged at 7 days (IQR, 4–10).

DISCUSSION

Principal findings

In this tertiary teaching hospital, a microbiologist-led AMS and IPC programme was associated with a 42% lower overall HAI incidence. The ITS level change was 37% and survived adjustment for case mix. Every HAI type declined, and CLABSI showed the largest relative fall. Carbapenem use fell by over a third, and the share of Access antibiotics rose by 10 percentage points. Carbapenem resistance fell in K pneumoniae, A baumannii and P aeruginosa, and hospital-onset CRE, CRAB and MRSA incidence fell by 31% to 43%. Mortality did not rise. Resistance in community-onset E coli, which the intervention should not affect, did not change. This makes a hospital-wide secular trend or a laboratory artefact an unlikely explanation.

 

Mechanisms

The two arms of the intervention probably worked through different but reinforcing pathways. The IPC arm acted directly on infection risk. Bundle compliance roughly doubled, hand hygiene compliance rose by 33 points, and daily review of device need reduced catheter and central line use. The device utilisation ratios fell, so part of the effect on device-associated infection came simply from fewer device-days. We therefore treated device use as a mediator and did not adjust for it.

The AMS arm reduced antibiotic selection pressure, mainly from carbapenems and polymyxins. Lower carbapenem exposure reduces the selective advantage of carbapenemase-producing strains. Contact precautions, admission screening and chlorhexidine bathing then limit their onward spread. The meta-analysis by Baur et al found that stewardship reduced MDR gram-negative colonisation and infection most when it was paired with infection control.¹² The fall in hospital-onset CRE and CRAB incidence (31% and 32%), larger than the fall in resistance proportions (7 to 8 points), fits this joint mechanism: fewer resistant organisms were acquired, and fewer patients were infected at all.

 

Comparison with previous studies

Our baseline device-associated infection rates were high compared with Indian network data. CLABSI was 11.4 and VAP 20.4 per 1000 device-days, against pooled INICC rates of 5.1 and 9.4 in Indian adult and paediatric ICUs.⁴ Higher baselines leave more room for improvement, which may partly explain the size of our effect. The 48% CLABSI reduction is close to the effect of checklist-based programmes in high-income ICUs.¹⁴ The 41% CAUTI reduction is larger than in a US national programme, where reductions were seen in non-ICU units but not in ICUs.³⁷

Our 17% fall in total consumption is close to the 19% pooled reduction reported in a meta-analysis of hospital stewardship programmes.³⁸ The 75% acceptance of PAF recommendations is higher than in the earlier stewardship programme at an Indian tertiary centre, which reported 54% acceptance.¹⁶ Daily presence of a clinical microbiologist on the wards, rather than written advice alone, may have helped.

A meta-analysis of Asian programmes found that stewardship reduced antibiotic use but improved HAI rates only when infection control or hand hygiene was part of the programme.¹⁵ Our data support that conclusion. They also add resistance and MDRO outcomes, which earlier Indian evaluations have rarely reported.¹⁶˒¹⁷

 

Resistance outcomes

The resistance changes were modest and organism-specific, as expected over 12 months. A baumannii stayed above 80% carbapenem resistant after the intervention. This matches the hyperendemic levels in Indian ICUs, where it is one of the hardest pathogens to control by stewardship alone.⁵˒⁶ The changes in carbapenem-resistant E coli, MRSA and VRE did not reach significance. The study had limited power for these smaller isolate groups, and these results should not be read as evidence of no effect. Without molecular typing we cannot tell whether the declines reflect less clonal transmission or less selection; both mechanisms are plausible.³⁹

 

Implications for practice

Most Indian hospitals do not have infectious diseases physicians or specialist pharmacists. This programme was led by a clinical microbiologist and used existing staff, printed checklists and the hospital antibiogram. Most components cost little: handrub, checklists, audits and feedback. The model fits the ICMR AMSP guideline and the hospital-level actions in the National Action Plan on AMR 2.0.¹⁸˒¹⁹ The early level drop and the continuing downward slope in carbapenem use suggest that the changes held over the year. Sustainment beyond 12 months still needs to be shown.

Hospitals planning similar programmes should run AMS and IPC together, not in sequence. They should also measure process, outcome and balancing indicators from the start.⁴⁰

 

Strengths and limitations

The study has several strengths. HAI surveillance used the same definitions and team in both periods, and data were collected prospectively. Twelve monthly points on each side of the intervention allowed segmented regression. A nonequivalent dependent variable tested for secular confounding. Process measures documented that the intervention was delivered, and balancing measures checked for harm.

The study also has important limitations:

  • No concurrent control. This was a single-centre study without a control hospital. ITS analysis reduces but does not remove confounding by co-interventions or external events.²⁰
  • Surveillance and Hawthorne effects. Greater awareness among staff may have changed behaviour beyond the planned components. Ascertainment may also have changed: better culture practice can either reveal or reduce HAIs. VAP definitions involve clinical judgement.
  • Resistance measurement. Resistance proportions depend on who gets cultured. The rise in cultures taken before antibiotics may have changed the mix of tested isolates. We deduplicated to the first isolate per patient to limit this.
  • Short follow-up. Twelve months is short for resistance outcomes and for sustainment.
  • Component effects. The intervention was a bundle, so the effect of each component cannot be separated.
  • Power. The study was not powered for mortality or for the smaller organism groups.
  • Scope. Costs and molecular epidemiology were not measured. The study units excluded paediatric and neonatal care, which limits generalisability.
CONCLUSION

A structured, microbiologist-led programme combining antimicrobial stewardship with infection prevention and control was associated, within 12 months, with 42% fewer HAIs, 36% less carbapenem use and lower carbapenem resistance in the main gram-negative pathogens. It did not increase mortality. The programme used existing staff and low-cost tools, so Indian tertiary hospitals implementing the National Action Plan on AMR 2.0 could adopt it.

Priorities for future research:

  1. Multicentre controlled ITS or stepped-wedge studies to confirm the effect and estimate the contribution of each component.
  2. Follow-up for 3 years or longer to test whether the reductions in resistance and HAI persist.
  3. Molecular typing of carbapenemase genes and clones to separate reduced transmission from reduced selection.
  4. Economic evaluation of cost per HAI averted and per DOT saved.
  5. Extension and adaptation to neonatal, paediatric and district-hospital settings.
REFERENCES
  1. Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629-655. doi:10.1016/S0140-6736(21)02724-0
  2. World Health Organization. Global Antibiotic Resistance Surveillance Report 2025. World Health Organization; 2025. Accessed November 4, 2026. https://www.who.int/publications/i/item/9789240116337
  3. Allegranzi B, Bagheri Nejad S, Combescure C, et al. Burden of endemic health-care-associated infection in developing countries: systematic review and meta-analysis. Lancet. 2011;377(9761):228-241. doi:10.1016/S0140-6736(10)61458-4
  4. Mehta Y, Jaggi N, Rosenthal VD, et al. Device-associated infection rates in 20 cities of India, data summary for 2004-2013: findings of the International Nosocomial Infection Control Consortium. Infect Control Hosp Epidemiol. 2016;37(2):172-181. doi:10.1017/ice.2015.276
  5. Mathur P, Malpiedi P, Walia K, et al; Indian Healthcare Associated Infection Surveillance Network collaborators. Health-care-associated bloodstream and urinary tract infections in a network of hospitals in India: a multicentre, hospital-based, prospective surveillance study. Lancet Glob Health. 2022;10(9):e1317-e1325. doi:10.1016/S2214-109X(22)00274-1
  6. Indian Council of Medical Research. Antimicrobial Resistance Research and Surveillance Network: Annual Report, January-December 2024. Indian Council of Medical Research; 2025. Accessed November 4, 2026. https://www.icmr.gov.in/icmrobject/uploads/Report/1763981012_icmramrsnannualreport2024.pdf
  7. Laxminarayan R, Chaudhury RR. Antibiotic resistance in India: drivers and opportunities for action. PLoS Med. 2016;13(3):e1001974. doi:10.1371/journal.pmed.1001974
  8. Dyar OJ, Huttner B, Schouten J, Pulcini C; ESGAP (ESCMID Study Group for Antimicrobial stewardshiP). What is antimicrobial stewardship? Clin Microbiol Infect. 2017;23(11):793-798. doi:10.1016/j.cmi.2017.08.026
  9. Barlam TF, Cosgrove SE, Abbo LM, et al. Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis. 2016;62(10):e51-e77. doi:10.1093/cid/ciw118
  10. World Health Organization. Guidelines on Core Components of Infection Prevention and Control Programmes at the National and Acute Health Care Facility Level. World Health Organization; 2016.
  11. Davey P, Marwick CA, Scott CL, et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev. 2017;2(2):CD003543. doi:10.1002/14651858.CD003543.pub4
  12. Baur D, Gladstone BP, Burkert F, et al. Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and Clostridium difficile infection: a systematic review and meta-analysis. Lancet Infect Dis. 2017;17(9):990-1001. doi:10.1016/S1473-3099(17)30325-0
  13. Pittet D, Hugonnet S, Harbarth S, et al. Effectiveness of a hospital-wide programme to improve compliance with hand hygiene. Lancet. 2000;356(9238):1307-1312. doi:10.1016/S0140-6736(00)02814-2
  14. Pronovost P, Needham D, Berenholtz S, et al. An intervention to decrease catheter-related bloodstream infections in the ICU. N Engl J Med. 2006;355(26):2725-2732. doi:10.1056/NEJMoa061115
  15. Lee CF, Cowling BJ, Feng S, et al. Impact of antibiotic stewardship programmes in Asia: a systematic review and meta-analysis. J Antimicrob Chemother. 2018;73(4):844-851. doi:10.1093/jac/dkx492
  16. Singh S, Menon VP, Mohamed ZU, et al. Implementation and impact of an antimicrobial stewardship program at a tertiary care center in South India. Open Forum Infect Dis. 2019;6(4):ofy290. doi:10.1093/ofid/ofy290
  17. Walia K, Ohri VC, Madhumathi J, Ramasubramanian V. Policy document on antimicrobial stewardship practices in India. Indian J Med Res. 2019;149(2):180-184. doi:10.4103/ijmr.IJMR_147_18
  18. Indian Council of Medical Research. Antimicrobial Stewardship Program Guideline. Indian Council of Medical Research; 2018.
  19. Ministry of Health and Family Welfare, Government of India. National Action Plan on Antimicrobial Resistance 2.0 (2025-2029). Ministry of Health and Family Welfare; 2025.
  20. Harris AD, Bradham DD, Baumgarten M, Zuckerman IH, Fink JC, Perencevich EN. The use and interpretation of quasi-experimental studies in infectious diseases. Clin Infect Dis. 2004;38(11):1586-1591. doi:10.1086/420936
  21. Des Jarlais DC, Lyles C, Crepaz N; TREND Group. Improving the reporting quality of nonrandomized evaluations of behavioral and public health interventions: the TREND statement. Am J Public Health. 2004;94(3):361-366. doi:10.2105/ajph.94.3.361
  22. Stone SP, Cooper BS, Kibbler CC, et al. The ORION statement: guidelines for transparent reporting of outbreak reports and intervention studies of nosocomial infection. Lancet Infect Dis. 2007;7(4):282-288. doi:10.1016/S1473-3099(07)70082-8
  23. Ogrinc G, Davies L, Goodman D, Batalden P, Davidoff F, Stevens D. SQUIRE 2.0 (Standards for QUality Improvement Reporting Excellence): revised publication guidelines from a detailed consensus process. BMJ Qual Saf. 2016;25(12):986-992. doi:10.1136/bmjqs-2015-004411
  24. Sax H, Allegranzi B, Uçkay I, Larson E, Boyce J, Pittet D. 'My five moments for hand hygiene': a user-centred design approach to understand, train, monitor and report hand hygiene. J Hosp Infect. 2007;67(1):9-21. doi:10.1016/j.jhin.2007.06.004
  25. Buetti N, Marschall J, Drees M, et al. Strategies to prevent central line-associated bloodstream infections in acute-care hospitals: 2022 update. Infect Control Hosp Epidemiol. 2022;43(5):553-569. doi:10.1017/ice.2022.87
  26. Klompas M, Branson R, Cawcutt K, et al. Strategies to prevent ventilator-associated pneumonia, ventilator-associated events, and nonventilator hospital-acquired pneumonia in acute-care hospitals: 2022 update. Infect Control Hosp Epidemiol. 2022;43(6):687-713. doi:10.1017/ice.2022.88
  27. Patel PK, Advani SD, Kofman AD, et al. Strategies to prevent catheter-associated urinary tract infections in acute-care hospitals: 2022 update. Infect Control Hosp Epidemiol. 2023;44(8):1209-1231. doi:10.1017/ice.2023.137
  28. Calderwood MS, Anderson DJ, Bratzler DW, et al. Strategies to prevent surgical site infections in acute-care hospitals: 2022 update. Infect Control Hosp Epidemiol. 2023;44(5):695-720. doi:10.1017/ice.2023.67
  29. World Health Organization. AWaRe Classification of Antibiotics for Evaluation and Monitoring of Use, 2023. World Health Organization; 2023. WHO/MHP/HPS/EML/2023.04.
  30. Centers for Disease Control and Prevention. National Healthcare Safety Network (NHSN) Patient Safety Component Manual. Centers for Disease Control and Prevention; January 2024.
  31. Polk RE, Fox C, Mahoney A, Letcavage J, MacDougall C. Measurement of adult antibacterial drug use in 130 US hospitals: comparison of defined daily dose and days of therapy. Clin Infect Dis. 2007;44(5):664-670. doi:10.1086/511640
  32. Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268-281. doi:10.1111/j.1469-0691.2011.03570.x
  33. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. 34th ed. CLSI supplement M100. Clinical and Laboratory Standards Institute; 2024.
  34. Penfold RB, Zhang F. Use of interrupted time series analysis in evaluating health care quality improvements. Acad Pediatr. 2013;13(6 suppl):S38-S44. doi:10.1016/j.acap.2013.08.002
  35. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther. 2002;27(4):299-309. doi:10.1046/j.1365-2710.2002.00430.x
  36. Bernal JL, Cummins S, Gasparrini A. Interrupted time series regression for the evaluation of public health interventions: a tutorial. Int J Epidemiol. 2017;46(1):348-355. doi:10.1093/ije/dyw098
  37. Saint S, Greene MT, Krein SL, et al. A program to prevent catheter-associated urinary tract infection in acute care. N Engl J Med. 2016;374(22):2111-2119. doi:10.1056/NEJMoa1504906
  38. Karanika S, Paudel S, Grigoras C, Kalbasi A, Mylonakis E. Systematic review and meta-analysis of clinical and economic outcomes from the implementation of hospital-based antimicrobial stewardship programs. Antimicrob Agents Chemother. 2016;60(8):4840-4852. doi:10.1128/AAC.00825-16
  39. Tacconelli E, Cataldo MA, Dancer SJ, et al. ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant gram-negative bacteria in hospitalized patients. Clin Microbiol Infect. 2014;20(suppl 1):1-55. doi:10.1111/1469-0691.12427
  40. Zingg W, Holmes A, Dettenkofer M, et al. Hospital organisation, management, and structure for prevention of health-care-associated infection: a systematic review and expert consensus. Lancet Infect Dis. 2015;15(2):212-224. doi:10.1016/S1473-3099(14)70854-0
Recommended Articles
Research Article
Geriatric Neurosurgery: Need of Developing A Practice Protocol-Experience In A Tertiary Care Hospital Of Western Odisha
...
Published: 18/11/2026
Research Article
Respiratory Symptoms and Spirometric Airflow Obstruction among Adult Smokers and Non-Smokers: A Comparative Cross-Sectional Study
Published: 18/11/2026
Research Article
Association Between Dietary Habits, Physical Activity, and Obesity Among University Students: A Cross-Sectional Study.
...
Published: 17/11/2026
Research Article
Comparative Assessment of Collagen Membrane and Platelet-Rich Fibrin for Bone Regeneration in Mandibular Odontogenic Cyst Defect.
...
Published: 18/11/2026
Chat on WhatsApp
© Copyright CME Journal Geriatric Medicine